80 related articles for article (PubMed ID: 38635661)
1. A distinct isoform of lymphoid enhancer binding factor 1 (LEF1) epigenetically restricts EBV reactivation to maintain viral latency.
Ward BJH; Prasai K; Schaal DL; Wang J; Scott RS
PLoS Pathog; 2023 Dec; 19(12):e1011873. PubMed ID: 38113273
[TBL] [Abstract][Full Text] [Related]
2. Retinoblastoma Protein Is Required for Epstein-Barr Virus Replication in Differentiated Epithelia.
Myers JE; Schaal DL; Nkadi EH; Ward BJH; Bienkowska-Haba M; Sapp M; Bodily JM; Scott RS
J Virol; 2023 Feb; 97(2):e0103222. PubMed ID: 36719239
[TBL] [Abstract][Full Text] [Related]
3. EBV Reactivation and Lymphomagenesis: More Questions than Answers.
Ford M; Orlando E; Amengual JE
Curr Hematol Malig Rep; 2023 Dec; 18(6):226-233. PubMed ID: 37566338
[TBL] [Abstract][Full Text] [Related]
4. Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection.
Inagaki T; Sato Y; Ito J; Takaki M; Okuno Y; Yaguchi M; Masud HMAA; Watanabe T; Sato K; Iwami S; Murata T; Kimura H
Front Microbiol; 2020; 11():575255. PubMed ID: 33613459
[TBL] [Abstract][Full Text] [Related]
5. Update of Natural Products and Their Derivatives Targeting Epstein-Barr Infection.
Pennisi R; Trischitta P; Costa M; Venuti A; Tamburello MP; Sciortino MT
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257824
[TBL] [Abstract][Full Text] [Related]
6. COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway.
Gandhi J; Gaur N; Khera L; Kaul R; Robertson ES
Virology; 2015 Oct; 484():1-14. PubMed ID: 26057147
[TBL] [Abstract][Full Text] [Related]
7. Targeted eradication of EBV-positive cancer cells by CRISPR/dCas9-mediated EBV reactivation in combination with ganciclovir.
Sugiokto FG; Li R
mBio; 2024 Jun; ():e0079524. PubMed ID: 38874417
[TBL] [Abstract][Full Text] [Related]
8. Unstable EBV latency drives inflammation in multiple sclerosis patient derived spontaneous B cells.
Soldan S; Su C; Monaco MC; Brown N; Clauze A; Andrada F; Feder A; Planet P; Kossenkov A; Schäffer D; Ohayon J; Auslander N; Jacobson S; Lieberman P
Res Sq; 2023 Feb; ():. PubMed ID: 36778367
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the latent-lytic switch in Epstein-Barr virus.
Kenney SC; Mertz JE
Semin Cancer Biol; 2014 Jun; 26():60-8. PubMed ID: 24457012
[TBL] [Abstract][Full Text] [Related]
10. Lytic cycle switches of oncogenic human gammaherpesviruses.
Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein-Barr virus lytic reactivation.
Gorres KL; Reineke DM; Miller G
PLoS One; 2024; 19(4):e0299198. PubMed ID: 38635661
[TBL] [Abstract][Full Text] [Related]
12. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.
Daigle D; Gradoville L; Tuck D; Schulz V; Wang'ondu R; Ye J; Gorres K; Miller G
J Virol; 2011 Jun; 85(11):5628-43. PubMed ID: 21411522
[TBL] [Abstract][Full Text] [Related]
14. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
